Pfizer (NYSE:PFE) Shares Up 3% – Here’s What Happened

Pfizer Inc. (NYSE:PFE) shares shot up 3% during mid-day trading on Wednesday. The company traded as high as $29.49 and last traded at $29.2170. 39,282,235 shares were traded during trading, a decline of 2% from the average daily volume of 40,269,410 shares. The stock had previously closed at $28.37.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Recent FDA approval of a new Tukysa treatment regimen could strengthen Pfizer’s oncology portfolio and improve the investment case by adding potential growth beyond its COVID-19 products. Tukysa Approval Might Change The Case For Investing In Pfizer Stock
• Positive Sentiment: Income-focused investors continue to favor Pfizer because of its roughly 6% dividend yield. Articles comparing Pfizer with GSK, Clorox and other high-yield stocks frame the dividend as compensation while investors wait for pipeline and earnings improvement. Better Dividend Stock: Pfizer vs. GSK
• Neutral Sentiment: Pfizer has been more stable than Moderna and Novavax during a broad vaccine-stock selloff, suggesting investors view its diversified pharmaceutical and oncology operations as a partial buffer against vaccine-related weakness. Novavax Plunges as Selloff Hits Vaccine Makers
• Negative Sentiment: Pfizer terminated its Phase 2 study of PF-06835375 in immune thrombocytopenia. The announcement removes a development program from the pipeline and raises questions about the drug’s prospects, although no detailed efficacy or safety rationale was provided in the report. Pfizer Halts Mid-Stage ITP Trial
• Negative Sentiment: Analysts expect Pfizer’s third-quarter profit to decline by double digits, creating a near-term earnings overhang ahead of next month’s report. This is especially important as the company continues replacing pandemic-era revenue with newer products. What to Expect From Pfizer’s Q3 2026 Earnings Report

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Scotiabank raised their price target on Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. BMO Capital Markets decreased their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Cantor Fitzgerald upped their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday. Five analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $28.72.

Pfizer Trading Up 0.4%

The firm has a market cap of $168.40 billion, a price-to-earnings ratio of 38.89, a PEG ratio of 1.98 and a beta of 0.32. The business has a fifty day moving average of $27.94 and a two-hundred day moving average of $26.55. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm earned $0.78 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 5.8%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio is presently 226.32%.

Institutional Investors Weigh In On Pfizer

A number of institutional investors have recently modified their holdings of the stock. Bank of America Corp DE bought a new stake in shares of Pfizer during the 2nd quarter valued at about $1,049,602,000. BlackRock Inc. lifted its holdings in Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares during the last quarter. Nykredit A S acquired a new position in Pfizer in the second quarter valued at approximately $205,774,000. Assenagon Asset Management S.A. boosted its stake in Pfizer by 96.0% in the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock valued at $286,609,000 after acquiring an additional 5,829,204 shares during the period. Finally, State Street Corp grew its holdings in shares of Pfizer by 1.8% during the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.